Analysts Offer Predictions for ELDN Q1 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Eledon Pharmaceuticals in a research note issued to investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.28) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.29) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same quarter last year, the company posted ($1.00) EPS.

Separately, Guggenheim initiated coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They issued a “buy” rating and a $9.00 price objective on the stock.

Eledon Pharmaceuticals Stock Up 2.8 %

NASDAQ:ELDN opened at $3.61 on Tuesday. The business’s 50-day moving average price is $4.16 and its 200 day moving average price is $3.88. Eledon Pharmaceuticals has a 52-week low of $1.52 and a 52-week high of $5.54. The firm has a market cap of $215.66 million, a P/E ratio of -1.80 and a beta of 0.80.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its stake in Eledon Pharmaceuticals by 418.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after buying an additional 6,412 shares in the last quarter. Alpine Global Management LLC acquired a new stake in shares of Eledon Pharmaceuticals during the fourth quarter valued at approximately $56,000. ADAR1 Capital Management LLC purchased a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $66,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eledon Pharmaceuticals in the 4th quarter worth approximately $76,000. Finally, Virtu Financial LLC purchased a new position in Eledon Pharmaceuticals during the 4th quarter worth approximately $82,000. 56.77% of the stock is owned by institutional investors and hedge funds.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).